Holen Sie sich die Stockscreener-App
39.77
0.53%
-0.21
Handel nachbörslich:
39.27
-0.50
-1.26%
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches - TradingView
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com India
Why Did Roivant (NASDAQ:ROIV) Shares Surge on Study Results? - Kalkine Media
Roivant Sciences Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $46 to $55 - Moomoo
ROIV Maintains Buy Rating -- Price Target Raised to $55 - GuruFocus
Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial - Pulse 2.0
Guggenheim raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com Australia
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com Australia
H.C. Wainwright raises Roivant Sciences price target on trial data - investing.com
Guggenheim raises Roivant Sciences stock price target on trial data - Investing.com
Roivant Sciences Stock Rallies 20% On Positive Phase 2 Trial Results For Pulmovant Drug - TIKR.com
Roivant Sciences stock surges on positive PH-ILD trial data By Investing.com - Investing.com Australia
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? - finance.yahoo.com
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41% - Yahoo Finance
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com Australia
Biotech Trial Wins Sent Roivant And Pharvaris Higher - Finimize
Roivant Sciences Ltd. (ROIV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ROIV Looks 472.1% Overvalued on GF Value™ Amid Clinical Trial Su - GuruFocus
Roivant Sciences soars 19% on positive mosliciguat trial results (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences (NASDAQ: ROIV) director moves to sell shares after option exercise - Stock Titan
Roivant Sciences Surges 17.7% Amid Sector-Wide Rally - AlphaStreet
ROIV Maintained by HC Wainwright & Co. -- Price Target Raised to $47 - GuruFocus
Roivant's experimental lung disease drug meets goals in mid-stage study - Reuters
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies? - Yahoo Finance
Roivant shares jump 17% as lung disease drug meets trial goals - Investing.com Canada
Jefferies raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com South Africa
Roivant Sciences price target jumps 24.7% after strong Phase 2 trial for lung disease drug - Pluang
Roivant Sciences Stock Soars as Experimental Inhaled Drug Hits Mid-Stage Trial Goals - barrons.com
ROIV Stock Jumps As FDA Clears LISRAYA And Analysts Hike Targets - StocksToTrade
ROIV Stock Jumps As LISRAYA FDA Approval Ignites Momentum - timothysykes.com
Roivant at Wells Fargo conference: pipeline momentum lifts outlook By Investing.com - Investing.com Canada
Transcript : Roivant Sciences Ltd. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 10:15 AM - marketscreener.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings - Benzinga
Jefferies Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Roivant Shares Surge as Mosliciguat Hits Primary Endpoint in Phase 2 PH-ILD Study - Minichart
Roivant Sciences Rallies as Mosliciguat Phase 2 Data Beat Key Endpoints - quiverquant.com
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy - Yahoo Finance
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data - BioSpace
Roivant Sciences stock hits all-time high at 39.99 USD By Investing.com - Investing.com Nigeria
Roivant Sciences stock surges on positive PH-ILD trial data - Investing.com
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Roivant Sciences stock hits all-time high at 39.99 USD - Investing.com
ROIV: Mosliciguat delivered unprecedented PVR reduction and functional gains in PH-ILD, with strong safety - TradingView
Up to 200,000 PH-ILD patients lack options as Roivant (NASDAQ: ROIV) moves mosliciguat into a Phase 3 trial - Stock Titan
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate - Yahoo Finance
ROIV Looks 381.9% Overvalued on GF Value™ - GuruFocus
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director - GlobeNewswire Inc.
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):